Clinical Trial Update: A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating AK117 in combination with azacitidine for higher-risk myelodysplastic syndromes is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• AK117 (AK117)
• AZACITIDINE (AZACITIDINE)

Snippet

Sponsor: Akeso | Conditions: Higher-risk Myelodysplastic Syndromes | Phase 2 | Status: RECRUITING